Skip to content
PubMed This is a summary of 50 peer-reviewed journal articles Updated
Endocrinology

LIPE-related Familial Partial Lipodystrophy: A Patient Guide

At a Glance

LIPE-related familial partial lipodystrophy (FPLD6) is a rare genetic condition that reduces fat storage under the skin, especially in the legs, and shifts fat to the upper body and organs, increasing risks of insulin resistance, high triglycerides, diabetes, and liver disease.

LIPE-related Familial Partial Lipodystrophy, often referred to as FPLD6, is an exceptionally rare genetic condition that fundamentally changes how your body stores and processes fat. Unlike common weight gain, which involves the expansion of fat tissue across the body, this condition is driven by a mutation in the LIPE gene. This gene is responsible for an enzyme that helps break down and manage stored fats. When it does not function correctly, the body loses the capacity to store fat safely under the skin, particularly in the legs. Instead, that fat accumulates ectopically in the upper body, face, and neck, and—more importantly—into the blood and internal organs [1][2]. It is important to know that this body distribution is not your fault.

The core challenge of living with FPLD6 is managing this ectopic fat accumulation. Because the body lacks the storage space it needs in the limbs, fat accumulates in places it typically would not be, such as the liver and the bloodstream. This leads to a suite of internal metabolic issues that are often much more severe than they might appear from the outside. Patients frequently face intense insulin resistance that can lead to early-onset diabetes, along with dangerously high levels of blood fats called triglycerides. If left unmanaged, these high fats can cause inflammation of the pancreas, while the fat stored in the liver can lead to long-term inflammation or scarring of that organ [3][4].

Beyond the metabolic effects, FPLD6 is considered a multi-system disorder that can affect other parts of the body. Because the LIPE gene is active in various tissues, some individuals have been reported to experience muscle weakness, known as myopathy, or develop specific yellow-white deposits in the back of the eyes. While these are not established features guaranteed to happen to everyone, these systemic signs highlight that the condition is not merely a cosmetic change in fat distribution, but a complex genetic syndrome that requires a broad, attentive approach to healthcare. Understanding these connections is the first step toward a management plan that protects your long-term health [1][3].

Navigating a diagnosis as rare as this can feel overwhelming, especially since many healthcare providers may be unfamiliar with the specific nuances of the LIPE variant. However, identifying the condition provides a clear roadmap for what to monitor and how to intervene. By working with a multidisciplinary team to manage blood sugars, protect the liver, and monitor systemic health, you can take an active role in steering your health journey. This guide is designed to empower you with the knowledge needed to have productive conversations with your specialists and to live confidently with this diagnosis [5][2].

Common questions in this guide

What is LIPE-related familial partial lipodystrophy, or FPLD6?
FPLD6 is a very rare genetic condition caused by a change in the LIPE gene. It reduces the body's ability to store fat safely under the skin, especially in the legs, so fat can build up in the upper body and internal organs.
Why can FPLD6 cause diabetes and high triglycerides?
When fat cannot be stored under the skin, it may collect in the bloodstream and organs, which can cause strong insulin resistance. This can lead to early-onset diabetes and very high triglycerides, which may inflame the pancreas if not managed.
Is the unusual fat distribution caused by my weight or lifestyle?
No. The characteristic fat distribution is linked to the LIPE gene mutation and is not your fault or simply common weight gain. Medical care focuses on managing the metabolic effects and protecting organs.
What health problems should people with FPLD6 watch for?
Important concerns include insulin resistance, early-onset diabetes, high triglycerides, inflammation of the pancreas, and liver inflammation or scarring. Some people may also have muscle weakness or yellow-white deposits at the back of the eyes, so new muscle or vision symptoms should be reported.
How is LIPE-related FPLD6 managed?
Management involves a coordinated care team that tracks blood sugar, triglycerides, liver health, and other system-specific concerns. Primary care, endocrine or genetics specialists, liver clinicians, and eye specialists may all contribute to care based on a person's needs.
What tests help distinguish FPLD6 from common metabolic syndrome?
Clinicians consider the pattern of fat loss and fat accumulation, the metabolic findings, and the person's LIPE genetic result. Blood tests can help assess blood sugar, triglycerides, and liver health, while the full clinical picture helps guide care.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Since this condition is so rare, how can we ensure my entire care team — from my primary doctor to my eye specialist — understands the unique risks of LIPE-related FPLD?
  2. 2.What is the most important metabolic number for us to track right now to protect my pancreas and liver?
  3. 3.How do we distinguish between my genetic fat distribution and the common metabolic syndrome using clinical and biochemical testing?
  4. 4.Are there specific symptoms, like muscle weakness or vision changes, that I should be reporting to you even if they seem unrelated to my weight or diet?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (5)
  1. 1

    LIPE-related lipodystrophic syndrome: clinical features and disease modeling using adipose stem cells.

    Sollier C, Capel E, Aguilhon C, et al.

    European journal of endocrinology 2021; (184(1)):155-168.

    PMID: 33112291
  2. 2

    Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy.

    Zolotov S, Xing C, Mahamid R, et al.

    American journal of medical genetics. Part A 2017; (173(1)):190-194 doi:10.1002/ajmg.a.37880.

    PMID: 27862896
  3. 3

    Case report: First Chinese patient with family partial lipodystrophy type 6 due to novel compound heterozygous mutations in the LIPE gene.

    Zhou Y, Zhang L, Ding Y, Zhai Y

    Frontiers in genetics 2024; (15()):1417613 doi:10.3389/fgene.2024.1417613.

    PMID: 39113684
  4. 4

    Approach to the Adult Patient with Chylomicronemia.

    Hegele RA

    The Journal of clinical endocrinology and metabolism 2026; (111(3)):845-859 doi:10.1210/clinem/dgaf701.

    PMID: 41472374
  5. 5

    Clinical Guidelines for the Diagnosis and Management of Generalized and Partial Lipodystrophies: A Position Statement Endorsed by the Hellenic Endocrine Society.

    Lambadiari V, Bargiota A, Kanaka-Gantenbein C, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(6)):1008-1016 doi:10.1016/j.eprac.2026.02.014.

    PMID: 41713690

This page explains LIPE-related familial partial lipodystrophy for informational purposes only and does not constitute medical advice. Your genetics, metabolic, liver, and eye care professionals should interpret your symptoms, laboratory results, and genetic findings.

Get notified when new evidence is published on LIPE-related familial partial lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.